Medicines under additional monitoring
In the European Union (EU), medicines that are being monitored particularly closely by regulatory authorities are labelled with a black inverted triangle (▼) in the product information. These medicines are described as being under 'additional monitoring'. The European Medicines Agency (EMA) maintains a list of all medicines that are under additional monitoring in the EU.
Medicines under additional monitoring have a black inverted triangle displayed in their package leaflet and in the information for healthcare professionals called the summary of product characteristics, together with a short sentence explaining what the triangle means:
This medicinal product is subject to additional monitoring.
The symbol does not appear on the outer packaging or labelling of medicines.
Additional monitoring aims to enhance reporting of suspected adverse drug reactions for medicines for which the clinical evidence base is less well developed. The main goals are to collect information as early as possible to further inform the safe and effective use of these medicines and their benefit-risk profile when used in everyday medical practice.
The concept of additional monitoring was introduced by the 2010 pharmacovigilance legislation, which came into effect in July 2012. The black triangle started appearing in the package leaflets of the medicines concerned from the autumn of 2013.
All medicines are carefully monitored after they are placed on the EU market. If a medicine is labelled with the black triangle, this means that it is being monitored even more intensively than other medicines.
This is generally because there is less information available on it than on other medicines, for example because it is new to the market or there is limited data on its long-term use.
It does not mean that the medicine is unsafe.
This video is available in español, Deutsch, français, italiano.
Additional monitoring status is always applied to a medicine in the following cases:
- it contains a new active substance authorised in the EU after 1 January 2011;
- it is a biological medicine, such as a vaccine or a medicine derived from plasma (blood), authorised in the EU after 1 January 2011;
- it has been given a conditional approval (where the company that markets the medicine must provide more data about it) or approved under exceptional circumstances (where there are specific reasons why the company cannot provide a comprehensive set of data);
- the company that markets the medicine is required to carry out additional studies, for instance, to provide more data on long-term use of the medicine or on a rare side effect seen during clinical trials;
- it is authorised with specific obligations on the recording of suspected adverse drug reactions.
Other medicines can also be placed under additional monitoring, based on advice from the Agency's Pharmacovigilance Risk Assessment Committee (PRAC).
The up-to-date list of medicines under additional monitoring is available on EMA's website and is also published by the national competent authorities in the EU Member States. The list is reviewed every month by the PRAC:
A medicine can be included on this list when it is approved for the first time or at any time during its life cycle. A medicine remains under additional monitoring for five years or until the PRAC decides to remove it from the list.
There may be a delay between the decision to add or remove a medicine from this list and the time when the updated package leaflet comes into circulation. This is because it takes some time for the updated package leaflet to gradually substitute older stock already on the EU market.
European regulatory authorities decide to authorise medicines after assessing their benefits and risks based on the results of clinical trials.
Only medicines whose benefits have been shown to be greater than their risks can reach the market. This ensures that patients can access the treatments they need without being exposed to unacceptable side effects.
Clinical trials involve a relatively small number of patients for a limited period of time. Patients in clinical trials are carefully selected and followed up very closely under controlled conditions.
In a real-life setting, a larger and more diverse group of patients will use the medicine. They may have other diseases and they may be taking other medicines. Some less common side effects may only occur once a medicine has been used for a long time by a large number of people.
It is therefore vital that the safety of all medicines continues to be monitored while they are in commercial use.
Information is continuously collected after a medicine is placed on the market to monitor real-life experience with the product. European regulatory authorities closely monitor this information to make sure that the benefits of medicines continue to outweigh their risks.
The same monitoring methods are used across the EU so that European regulatory authorities can share the information gathered in individual EU countries. This provides a wealth of knowledge for regulators to rely upon when making decisions, and enables them to act quickly to ensure patient safety when required, such as providing warnings to patients and healthcare professionals or restricting the way a medicine is used.
Reporting suspected side effects is an important way to gather more information on medicines on the market. Regulatory authorities look at reports of side effects alongside all the information they already have to make sure that the benefits of medicines remain greater than their risks and to take any necessary action.
Patients and healthcare professionals are encouraged to report suspected side effects seen with any medicine. Under the 2010 pharmacovigilance legislation, patients have the right to report suspected side effects directly to the national competent authorities in their country if they wish. Information on how to do this must be given in each medicine's package leaflet and summary of product characteristics.
The black triangle makes it possible to quickly identify medicines that are subject to additional monitoring. Patients and healthcare professionals are strongly encouraged to report any suspected side effects with medicines displaying the black triangle, so that any new emerging information can be analysed efficiently.
Update: The European Commission has published a report on the experience of monitoring the safety of medicines that are subject to additional monitoring. This review was required by the pharmacovigilance legislation and was based on a detailed contribution from EMA and Member States.
The report recommends that EMA and the Member States should continue to:
The joint Heads of Medicines Agencies (HMA)/EMA report that formed the basis of the European Commission's review summarises the experience with the additional monitoring scheme in the European medicines regulatory network since 2013, based on: